Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy

Basit Öğe Kaydı
dc.contributor.authorCil, Timucin
dc.contributor.authorAltintas, Abdullah
dc.contributor.authorPasa, Semir
dc.contributor.authorBayan, Kadim
dc.contributor.authorOzekinci, Tuncer
dc.contributor.authorIsikdogan, Abdurrahman
dc.date.accessioned2024-04-24T16:24:53Z
dc.date.available2024-04-24T16:24:53Z
dc.date.issued2008
dc.departmentDicle Üniversitesien_US
dc.description.abstractHepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide. Cancer patients who are chronic carriers of HBV have a higher hepatic complication rate while receiving cytotoxic chemotherapy (CT) and this has mainly been attributed to HBV reactivation. In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine. The objectives were to assess the efficacy of lamivudine in reducing the incidence of HBV reactivation, and diminishing morbidity and mortality during CT. Two groups were compared in this study. The prophylactic lamivudin group consisted of 37 patients who received prophylactic lamivudine treatment. The historical controls consisted of 50 consecutive patients who underwent CT without prophylactic lamivudine. They were followed up during and for 8 weeks after CT. The outcomes were compared for both groups. Of our control group (n= 50), 21 patients (42%) were established hepatitis. Twelve (24%) of them were evaluated as severe hepatitis. In the prophylactic lamivudine group severe hepatitis were observed only in 1 patient (2.7%) of 37 patients (p0.006). Comparison of the mean ALT values revealed significantly higher mean alanine aminotransferase (ALT) values in the control group than the prophylactic lamivudine group; 154:64 (p0.32). Our study suggests that prophylactic lamivudine significantly decreases the incidence of HBV reactivation and overall morbidity in cancer patients during and after immunosuppressive therapy. Further studies are needed to determine the most appropriate nucleoside or nucleotide analogue for antiviral prophylaxis during CT and the optimal duration of administration after completion of CT.en_US
dc.identifier.doi10.1080/10428190801975568
dc.identifier.endpage947en_US
dc.identifier.issn1042-8194
dc.identifier.issue5en_US
dc.identifier.pmid18464113
dc.identifier.scopus2-s2.0-46749098315
dc.identifier.scopusqualityQ2
dc.identifier.startpage939en_US
dc.identifier.urihttps://doi.org/10.1080/10428190801975568
dc.identifier.urihttps://hdl.handle.net/11468/16890
dc.identifier.volume49en_US
dc.identifier.wosWOS:000255688800021
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherInforma Healthcareen_US
dc.relation.ispartofLeukemia & Lymphoma
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHepatitis B Virusen_US
dc.subjectLamivudineen_US
dc.subjectHepatic Flare-Upen_US
dc.titleLamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapyen_US
dc.titleLamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu